Jack L. Sloane
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jack L. Sloane has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Trevor C. Sherwood
Discovery and Development Sciences
5 shared publications - Eric M. Simmons
Chemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States
4 shared publications - Paul A. Wender
Stanford University
3 shared publications - Akira Shimizu
Departments of Chemistry and of Chemical and Systems Biology, Stanford University, Stanford, CA, 94305, USA
2 shared publications - Antonio Ramirez
Chemical Process Development, Bristol Myers Squibb, New Brunswick, New Jersey 08903, United States
2 shared publications Christopher Levins
Bristol Myers Squibb, Route 206 and Province Line Rd., Princeton, New Jersey 08540, United States
2 shared publications
Latest Publications
- 2 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 5925-5934
Optimization of Covalent Warhead Trajectory for KRAS G12C Active-State Inhibition
We describe here the impact of the covalent warhead trajectory on biochemical active-state potency, covalent kinetics, cellular potency, and pharmacokinetic parameters for KRASG12C inhibitors. Using structure-based design augmented with computational models, trajectories were identified that successfully enhanced compound potency without requiring any additional optimization of the parent scaffold. In contrast to the trajectories of approved and clinical-stage KRASG12C inactive state-selective inhibitors, which largely consist of a collinear arrangement of the core, (di)amine linker, and covalent warhead, these trajectories were characterized by an angled disposition of the covalent warhead. A cocrystal structure implicated an increased distance from the bound nucleotide of KRASG12C as the basis for this increase in potency, suggesting a general design principle for targeting the active state of KRAS.
- 2 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 5925-5934
Optimization of Covalent Warhead Trajectory for KRAS G12C Active-State Inhibition
We describe here the impact of the covalent warhead trajectory on biochemical active-state potency, covalent kinetics, cellular potency, and pharmacokinetic parameters for KRASG12C inhibitors. Using structure-based design augmented with computational models, trajectories were identified that successfully enhanced compound potency without requiring any additional optimization of the parent scaffold. In contrast to the trajectories of approved and clinical-stage KRASG12C inactive state-selective inhibitors, which largely consist of a collinear arrangement of the core, (di)amine linker, and covalent warhead, these trajectories were characterized by an angled disposition of the covalent warhead. A cocrystal structure implicated an increased distance from the bound nucleotide of KRASG12C as the basis for this increase in potency, suggesting a general design principle for targeting the active state of KRAS.
- 2 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 5935-5943
Optimization of α-Fluoro, β-Heteroaryl Acrylamide Warheads for KRAS G12C Active-State Inhibition
We provide herein a detailed investigation of the warhead reactivity and pharmaceutical properties of a novel α-fluoro, β-heteroaryl acrylamide class of covalent warhead in the context of KRASG12C active-state inhibition. Unlike traditional unsubstituted acrylamide warheads, which undergo conjugate addition with cysteine at the β-position, these acrylamides react at the α-position in a vinylogous nucleophilic aromatic substitution (SNAr) transformation. Systematic examination of pyridine warhead substitutions and bioisosteric replacements elucidated a dependence of these warheads' reactivity on heterocycle basicity in addition to electrophilicity. In vitro characterization revealed the effects of heterocycle identity on cellular potency, free fraction, permeability, and efflux ratio. These lessons informed in vivo studies, culminating in the discovery of a lead molecule that showed low clearance across species and robust efficacy in a mouse xenograft model.
- 2 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 5935-5943
Optimization of α-Fluoro, β-Heteroaryl Acrylamide Warheads for KRAS G12C Active-State Inhibition
We provide herein a detailed investigation of the warhead reactivity and pharmaceutical properties of a novel α-fluoro, β-heteroaryl acrylamide class of covalent warhead in the context of KRASG12C active-state inhibition. Unlike traditional unsubstituted acrylamide warheads, which undergo conjugate addition with cysteine at the β-position, these acrylamides react at the α-position in a vinylogous nucleophilic aromatic substitution (SNAr) transformation. Systematic examination of pyridine warhead substitutions and bioisosteric replacements elucidated a dependence of these warheads' reactivity on heterocycle basicity in addition to electrophilicity. In vitro characterization revealed the effects of heterocycle identity on cellular potency, free fraction, permeability, and efflux ratio. These lessons informed in vivo studies, culminating in the discovery of a lead molecule that showed low clearance across species and robust efficacy in a mouse xenograft model.
- 24 April 2025
- Published by Elsevier
- p. 176-241
Photoredox Catalysis
- 25 August 2023
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 13 (18) , 11910-11918
Unlocking Tertiary Acids for Metallaphotoredox C(sp2)–C(sp3) Decarboxylative Cross-Couplings
- 25 August 2023
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 13 (18) , 11910-11918
Unlocking Tertiary Acids for Metallaphotoredox C(sp2)–C(sp3) Decarboxylative Cross-Couplings
- 6 June 2023
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 25 (23) , 4219-4224
Metallaphotoredox-Mediated Decarboxylative Cross-Coupling of α-Oxy Morpholine Carboxylic Acids and (Hetero)Aryl Halides
A decarboxylative C(sp2)-C(sp3) cross-coupling reaction of α-oxy carboxylic acids using dual nickel/photoredox catalysis has been developed for the synthesis of complex morpholines and other saturated heterocycles, affording direct entry to scaffolds of interest in drug discovery. This chemistry can be applied to the coupling of an array of (hetero)aryl halides and α-heteroatom acids, providing C(sp2)-C(sp3)-coupled products in modest to excellent yields and enabling access to intermediates that can be further derivatized to multivector architectures.
- 6 June 2023
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 25 (23) , 4219-4224
Metallaphotoredox-Mediated Decarboxylative Cross-Coupling of α-Oxy Morpholine Carboxylic Acids and (Hetero)Aryl Halides
A decarboxylative C(sp2)-C(sp3) cross-coupling reaction of α-oxy carboxylic acids using dual nickel/photoredox catalysis has been developed for the synthesis of complex morpholines and other saturated heterocycles, affording direct entry to scaffolds of interest in drug discovery. This chemistry can be applied to the coupling of an array of (hetero)aryl halides and α-heteroatom acids, providing C(sp2)-C(sp3)-coupled products in modest to excellent yields and enabling access to intermediates that can be further derivatized to multivector architectures.
- 15 November 2022
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 87 (23) , 15925-15937
Trimethylene Methane Dianion Equivalent for the Asymmetric Consecutive Allylation of Aldehydes: Applications to Prins-Driven Macrocyclizations for the Synthesis of Bryostatin 1 and Analogues
We report a one-step (one-flask) generation and reaction of a bifunctional allylating reagent, a trimethylene methane dianion equivalent, that provides a route for the asymmetric 2-(trimethylsilylmethyl) allylation of aldehydes. The product of the first aldehyde allylation process is then set to engage in a second separate aldehyde allylation, providing an improved Prins macrocyclization strategy both for the scalable synthesis of bryostatin 1 and for the total synthesis of a new potent bryostatin analogue.
- 15 November 2022
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 87 (23) , 15925-15937
Trimethylene Methane Dianion Equivalent for the Asymmetric Consecutive Allylation of Aldehydes: Applications to Prins-Driven Macrocyclizations for the Synthesis of Bryostatin 1 and Analogues
We report a one-step (one-flask) generation and reaction of a bifunctional allylating reagent, a trimethylene methane dianion equivalent, that provides a route for the asymmetric 2-(trimethylsilylmethyl) allylation of aldehydes. The product of the first aldehyde allylation process is then set to engage in a second separate aldehyde allylation, providing an improved Prins macrocyclization strategy both for the scalable synthesis of bryostatin 1 and for the total synthesis of a new potent bryostatin analogue.
- 3 August 2022
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 24 (31) , 5663-5668
Ni/Photoredox-Catalyzed C(sp2)–C(sp3) Cross-Coupling of Alkyl Pinacolboronates and (Hetero)Aryl Bromides
Utilizing quinoline as a mild, catalytic additive, broadly applicable conditions for the Ni/photoredox-catalyzed C(sp2)-C(sp3) cross-coupling of (hetero)aryl bromides and alkyl pinacolboronate esters were developed, which can be applied to both batch and flow reactions. In addition to primary benzylic nucleophiles, both stabilized and nonstabilized secondary alkyl boronic esters are effective coupling partners. Density functional theory calculations suggest that alkyl radical generation occurs from an alkyl-B(pin)-quinoline complex, which may proceed via an energy transfer process.
- 3 August 2022
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 24 (31) , 5663-5668
Ni/Photoredox-Catalyzed C(sp2)–C(sp3) Cross-Coupling of Alkyl Pinacolboronates and (Hetero)Aryl Bromides
Utilizing quinoline as a mild, catalytic additive, broadly applicable conditions for the Ni/photoredox-catalyzed C(sp2)-C(sp3) cross-coupling of (hetero)aryl bromides and alkyl pinacolboronate esters were developed, which can be applied to both batch and flow reactions. In addition to primary benzylic nucleophiles, both stabilized and nonstabilized secondary alkyl boronic esters are effective coupling partners. Density functional theory calculations suggest that alkyl radical generation occurs from an alkyl-B(pin)-quinoline complex, which may proceed via an energy transfer process.
- Open Access
- 20 April 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-11
Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy
Bryostatin 1 is a marine natural product under investigation for HIV/AIDS eradication, the treatment of neurological disorders, and enhanced CAR T/NK cell immunotherapy. Despite its promising activity, bryostatin 1 is neither evolved nor optimized for the treatment of human disease. Here we report the design, synthesis, and biological evaluation of several close-in analogs of bryostatin 1. Using a function-oriented synthesis approach, we synthesize a series of bryostatin analogs designed to maintain affinity for bryostatin’s target protein kinase C (PKC) while enabling exploration of their divergent biological functions. Our late-stage diversification strategy provides efficient access to a library of bryostatin analogs, which per our design retain affinity for PKC but exhibit variable PKC translocation kinetics. We further demonstrate that select analogs potently increase cell surface expression of CD22, a promising CAR T cell target for the treatment of leukemias, highlighting the clinical potential of bryostatin analogs for enhancing targeted immunotherapies.
- 20 April 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-11
Open AccessSynthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy
Bryostatin 1 is a marine natural product under investigation for HIV/AIDS eradication, the treatment of neurological disorders, and enhanced CAR T/NK cell immunotherapy. Despite its promising activity, bryostatin 1 is neither evolved nor optimized for the treatment of human disease. Here we report the design, synthesis, and biological evaluation of several close-in analogs of bryostatin 1. Using a function-oriented synthesis approach, we synthesize a series of bryostatin analogs designed to maintain affinity for bryostatin’s target protein kinase C (PKC) while enabling exploration of their divergent biological functions. Our late-stage diversification strategy provides efficient access to a library of bryostatin analogs, which per our design retain affinity for PKC but exhibit variable PKC translocation kinetics. We further demonstrate that select analogs potently increase cell surface expression of CD22, a promising CAR T cell target for the treatment of leukemias, highlighting the clinical potential of bryostatin analogs for enhancing targeted immunotherapies.
- 13 October 2017
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 358 (6360) , 218-223
Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV
A gram-scale route to bryostatin: Scientists once accumulated 14 tons of the red, bushy, tufted sea creature Bugula neritina to extract 18 grams of bryostatin 1. The macrocyclic organic compound is under study for treatment of HIV, cancer, and Alzheimer's disease but has proven frustratingly scarce. Wender et al. report a 29-step chemical synthesis of bryostatin 1 that proceeds in 4.8% overall yield and provides gram quantities of the compound (see the Perspective by Lanman). Intermediates along the pathway can be straightforwardly modified to produce analogs, two of which were prepared en route and studied in vitro. Science , this issue p. 218 ; see also p. 166
- 13 October 2017
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 358 (6360) , 218-223
Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV
A gram-scale route to bryostatin: Scientists once accumulated 14 tons of the red, bushy, tufted sea creature Bugula neritina to extract 18 grams of bryostatin 1. The macrocyclic organic compound is under study for treatment of HIV, cancer, and Alzheimer's disease but has proven frustratingly scarce. Wender et al. report a 29-step chemical synthesis of bryostatin 1 that proceeds in 4.8% overall yield and provides gram quantities of the compound (see the Perspective by Lanman). Intermediates along the pathway can be straightforwardly modified to produce analogs, two of which were prepared en route and studied in vitro. Science , this issue p. 218 ; see also p. 166